Pharming Group (NASDAQ:PHAR) Given New $30.00 Price Target at Oppenheimer

Pharming Group (NASDAQ:PHAR) had its price objective decreased by Oppenheimer from $31.00 to $30.00 in a research note issued to investors on Monday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday, October 24th.

Pharming Group Stock Performance

NASDAQ PHAR opened at $8.91 on Monday. The company has a market cap of $604.41 million, a PE ratio of -34.27 and a beta of 0.15. The stock’s 50 day simple moving average is $8.12 and its 200-day simple moving average is $8.50. Pharming Group has a 1-year low of $6.65 and a 1-year high of $13.20. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The company had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. During the same quarter in the previous year, the business posted $0.02 EPS. As a group, equities research analysts anticipate that Pharming Group will post -0.15 EPS for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.